

Masayoshi Shichiri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5126203/publications.pdf>

Version: 2024-02-01

164
papers

7,381
citations

47006
47
h-index

62596
80
g-index

166
all docs

166
docs citations

166
times ranked

6895
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical feasibility of remote intermittently scanned continuous glucose monitoring in coronavirus disease 2019 patients with and without diabetes during dexamethasone therapy. <i>Endocrine Journal</i> , 2022, 69, 597-604.	1.6	1
2	Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes. <i>Endocrine Journal</i> , 2022, 69, 681-687.	1.6	4
3	Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108225.	2.3	1
4	Plasma and serum prorenin concentrations in diabetes, hypertension, and renal disease. <i>Hypertension Research</i> , 2022, 45, 1977-1985.	2.7	3
5	Randomized study of prevention of gastrointestinal toxicities by nutritional support using an amino acid-rich elemental diet during chemotherapy in patients with esophageal cancer (KDOC 1101). <i>Esophagus</i> , 2021, 18, 296-305.	1.9	4
6	The effectiveness of growth hormone replacement on energy expenditure and body composition in patients with adult growth hormone deficiency. <i>Endocrine Journal</i> , 2021, 68, 469-475.	1.6	4
7	Circulating prorenin: its molecular forms and plasma concentrations. <i>Hypertension Research</i> , 2021, 44, 674-684.	2.7	5
8	Hemodialysis-Related Glycemic Disarray Proven by Continuous Glucose Monitoring; Glycemic Markers and Hypoglycemia. <i>Diabetes Care</i> , 2021, 44, 1647-1656.	8.6	15
9	GIP_HUMAN[22â€“51] is a new proatherogenic peptide identified by native plasma peptidomics. <i>Scientific Reports</i> , 2021, 11, 14470.	3.3	5
10	Suprabasin-derived bioactive peptides identified by plasma peptidomics. <i>Scientific Reports</i> , 2021, 11, 1047.	3.3	8
11	Protein arginine N-methyltransferase 1 gene polymorphism is associated with proliferative diabetic retinopathy in a Japanese population. <i>Acta Diabetologica</i> , 2021, , 1.	2.5	1
12	Comparison of accuracy between flash glucose monitoring and continuous glucose monitoring in patients with type 2 diabetes mellitus undergoing hemodialysis. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107680.	2.3	13
13	Oxidised Met147 of human serum albumin is a biomarker of oxidative stress, reflecting glycaemic fluctuations and hypoglycaemia in diabetes. <i>Scientific Reports</i> , 2020, 10, 268.	3.3	18
14	Use of Noncontact Infrared Skin Thermometer for Peripheral Arterial Disease Screening in Patients With and Without Diabetes. <i>Angiology</i> , 2020, 71, 650-657.	1.8	3
15	Short-term Change in Resting Energy Expenditure and Body Compositions in Therapeutic Process for Graves' Disease. <i>Internal Medicine</i> , 2020, 59, 1827-1833.	0.7	5
16	Molecular form and concentration of serum \pm 2-macroglobulin in diabetes. <i>Scientific Reports</i> , 2019, 9, 12927.	3.3	38
17	Basal glucagon hypersecretion and response to oral glucose load in prediabetes and mild type 2 diabetes. <i>Endocrine Journal</i> , 2019, 66, 663-675.	1.6	33
18	Identification of plasma binding proteins for glucose-dependent insulinotropic polypeptide. <i>Endocrine Journal</i> , 2019, 66, 621-628.	1.6	3

#	ARTICLE	IF	CITATIONS
19	A novel strategy to identify autoantigens by proteomic analysis of plasma IgG-bound proteins. Journal of Electrophoresis, 2019, 63, 15-24.	0.4	1
20	Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. Journal of Diabetes Investigation, 2019, 10, 1004-1011.	2.4	69
21	Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide. Nephrology, 2018, 23, 883-886.	1.6	13
22	Identification of the salusin- $\hat{1}^2$ receptor using proteoliposomes embedded with endogenous membrane proteins. Scientific Reports, 2018, 8, 17865.	3.3	8
23	Distinct clinical characteristics and therapeutic modalities for diabetic ketoacidosis in type 1 and type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2017, 31, 468-472.	2.3	16
24	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology, 2017, 5, 951-964.	11.4	228
25	Identification and quantification of plasma free salusin- $\hat{1}^2$, an endogenous parasympathomimetic peptide. Scientific Reports, 2017, 7, 8275.	3.3	9
26	Methionine sulfoxides in serum proteins as potential clinical biomarkers of oxidative stress. Scientific Reports, 2016, 6, 38299.	3.3	61
27	Salusin- $\hat{1}^2$ as a powerful endogenous antidipsogenic neuropeptide. Scientific Reports, 2016, 6, 20988.	3.3	11
28	Vascular Endothelial Growth Factor Receptor Type 1 Signaling Prevents Delayed Wound Healing in Diabetes by Attenuating the Production of IL-1 $\hat{2}$ by Recruited Macrophages. American Journal of Pathology, 2016, 186, 1481-1498.	3.8	49
29	Contrasting effects of stanniocalcin-related polypeptides on macrophage foam cell formation and vascular smooth muscle cell migration. Peptides, 2016, 82, 120-127.	2.4	10
30	Levels of albuminuria and risk of developing macroalbuminuria in type 2 diabetes: historical cohort study. Scientific Reports, 2016, 6, 26380.	3.3	19
31	SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies. Endocrine Journal, 2016, 63, 187-191.	1.6	11
32	Distinct biomarker roles for HbA 1c and glycated albumin in patients with type 2 diabetes on hemodialysis. Journal of Diabetes and Its Complications, 2016, 30, 1494-1499.	2.3	33
33	Regulation of growth hormone secretion by (pro)renin receptor. Scientific Reports, 2015, 5, 10878.	3.3	15
34	Suppressed recruitment of alternatively activated macrophages reduces TGF- $\hat{1}^2$ 1 and impairs wound healing in streptozotocin-induced diabetic mice. Biomedicine and Pharmacotherapy, 2015, 70, 317-325.	5.6	108
35	Physiological fluctuations of human plasma total salusin- $\hat{1}^2$, an endogenous parasympathomimetic/proatherosclerotic peptide. Peptides, 2014, 59, 83-88.	2.4	4
36	Downregulation of the proangiogenic prostaglandin E receptor EP3 and reduced angiogenesis in a mouse model of diabetes mellitus. Biomedicine and Pharmacotherapy, 2014, 68, 1125-1133.	5.6	13

#	ARTICLE	IF	CITATIONS
37	Serum monomeric $\hat{1}\pm 2$ -macroglobulin as a clinical biomarker in \hat{A} diabetes. <i>Atherosclerosis</i> , 2013, 228, 270-276.	0.8	20
38	Salusins: Potential Use as a Biomarker for Atherosclerotic Cardiovascular Diseases. <i>International Journal of Hypertension</i> , 2013, 2013, 1-8.	1.3	43
39	Anti-salusin- $\hat{1}2$ antibody enhances angiogenesis after myocardial ischemia reperfusion injury. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 1003-1009.	3.4	17
40	Salusins. , 2013, , 1423-1427.		5
41	Circulating Levels of Human salusin- $\hat{1}2$, a Potent Hemodynamic and Atherogenesis Regulator. <i>PLoS ONE</i> , 2013, 8, e76714.	2.5	35
42	Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases. <i>Current Protein and Peptide Science</i> , 2013, 14, 472-480.	1.4	16
43	Salusin- $\hat{1}2$ accelerates inflammatory responses in vascular endothelial cells via NF- $\hat{1}B$ signaling in LDL receptor-deficient mice in vivo and HUVECs in vitro. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H96-H105.	3.2	52
44	Endogenous Bioactive Peptides as Potential Biomarkers for Atherosclerotic Coronary Heart Disease. <i>Sensors</i> , 2012, 12, 4974-4985.	3.8	23
45	Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo- and microalbuminuric type 2 diabetes. <i>Kidney International</i> , 2012, 81, 486-493.	5.2	72
46	Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. <i>Endocrine Journal</i> , 2012, 59, 221-228.	1.6	65
47	New Indices for Predicting Glycaemic Variability. <i>PLoS ONE</i> , 2012, 7, e46517.	2.5	76
48	Prolonged effects of intracerebroventricular angiotensin II on drinking, eating and locomotor behavior in mice. <i>Regulatory Peptides</i> , 2012, 173, 86-92.	1.9	9
49	Distinct systemic distribution of salusin- $\hat{1}\pm$ and salusin- $\hat{1}2$ in the rat. <i>Peptides</i> , 2011, 32, 805-810.	2.4	38
50	The roles of salusins in atherosclerosis and related cardiovascular diseases. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 359-365.	2.3	47
51	A Woman with Salt-wasting Congenital Adrenal Hyperplasia Presenting with a Mucinous Ovarian Cystadenoma during Pregnancy. <i>Internal Medicine</i> , 2011, 50, 1981-1985.	0.7	7
52	The (pro)renin receptor is cleaved by ADAM19 in the Golgi leading to its secretion into extracellular space. <i>Hypertension Research</i> , 2011, 34, 599-605.	2.7	111
53	Relationship between Autonomic Nervous System Activity during Sleep and Fasting Glucose in Japanese Workers. <i>Industrial Health</i> , 2011, 49, 427-433.	1.0	3
54	Inhibition of cancer progression by rifampicin: Involvement of antiangiogenic and anti-tumor effects. <i>Cell Cycle</i> , 2010, 9, 64-68.	2.6	16

#	ARTICLE	IF	CITATIONS
55	Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 1041-1047.	1.8	6
56	Upregulation of CDKN2A and suppression of cyclin D1 gene expressions in ACTH-secreting pituitary adenomas. <i>European Journal of Endocrinology</i> , 2010, 163, 523-529.	3.7	24
57	Release of salusin- $\hat{1}^2$ from human monocytes/macrophages. <i>Regulatory Peptides</i> , 2010, 162, 68-72.	1.9	31
58	Serum levels and urinary excretion of salusin- $\hat{1}\pm$ in renal insufficiency. <i>Regulatory Peptides</i> , 2010, 162, 129-132.	1.9	24
59	Chronic infusion of salusin- $\hat{1}\pm$ and - $\hat{1}^2$ exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. <i>Atherosclerosis</i> , 2010, 212, 70-77.	0.8	56
60	Rifampicin as an Oral Angiogenesis Inhibitor Targeting Hepatic Cancers. <i>Cancer Research</i> , 2009, 69, 4760-4768.	0.9	33
61	A Critical Role of Salusin-beta in Myocardial Ischemia. <i>Journal of Cardiac Failure</i> , 2009, 15, S172.	1.7	1
62	Presence of immunoreactive salusin- $\hat{1}^2$ in human plasma and urine. <i>Regulatory Peptides</i> , 2009, 158, 63-67.	1.9	39
63	Expression of prosalusin in human neuroblastoma cells. <i>Peptides</i> , 2009, 30, 1362-1367.	2.4	28
64	Biosynthesis and secretion of salusin- $\hat{1}\pm$ from human cells. <i>Peptides</i> , 2008, 29, 2203-2207.	2.4	17
65	Serum Salusin-.ALPHA. Levels Are Decreased and Correlated Negatively with Carotid Atherosclerosis in Essential Hypertensive Patients. <i>Hypertension Research</i> , 2008, 31, 463-468.	2.7	56
66	Impact of Salusin- $\hat{1}\pm$ and - $\hat{1}^2$ on Human Macrophage Foam Cell Formation and Coronary Atherosclerosis. <i>Circulation</i> , 2008, 117, 638-648.	1.6	121
67	Nitric Oxide Upregulates Dimethylarginine Dimethylaminohydrolase-2 via Cyclic GMP Induction in Endothelial Cells. <i>Hypertension</i> , 2008, 52, 903-909.	2.7	24
68	Systemic Distribution of Salusin Expression in the Rat. <i>Hypertension Research</i> , 2007, 30, 1255-1262.	2.7	59
69	Angiotensin II Receptor Type 1-Mediated Vascular Oxidative Stress and Proinflammatory Gene Expression in Aldosterone-Induced Hypertension: The Possible Role of Local Renin-Angiotensin System. <i>Endocrinology</i> , 2007, 148, 1688-1696.	2.8	100
70	Chronic Blockade of Nitric Oxide Synthesis Reduces Adiposity and Improves Insulin Resistance in High Fat-Induced Obese Mice. <i>Endocrinology</i> , 2007, 148, 4548-4556.	2.8	70
71	Differential gene expression in ACTH -secreting and non-functioning pituitary tumors. <i>European Journal of Endocrinology</i> , 2007, 157, 717-724.	3.7	83
72	Reply to 'Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities'. <i>Nature Medicine</i> , 2007, 13, 661-662.	30.7	19

#	ARTICLE	IF	CITATIONS
73	Presence of immunoreactive salusin- $\hat{1}\pm$ in human serum and urine. <i>Peptides</i> , 2006, 27, 2561-2566.	2.4	49
74	Salusin $\hat{1}^2$ is a surrogate ligand of the mas-like G protein-coupled receptor MrgA1. <i>European Journal of Pharmacology</i> , 2006, 539, 145-150.	3.5	34
75	Adrenomedullin Inhibits Angiotensin II-Induced Oxidative Stress and Gene Expression in Rat Endothelial Cells. <i>Hypertension Research</i> , 2005, 28, 165-172.	2.7	61
76	Concomitant expression of adrenomedullin and its receptor components in rat adipose tissues. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E56-E62.	3.5	37
77	Synthetic Salusins as Cardiac Depressors in Rat. <i>Hypertension</i> , 2005, 45, 419-425.	2.7	68
78	Aldosterone Induces Angiotensin Converting Enzyme Gene Expression via a JAK2-Dependent Pathway in Rat Endothelial Cells. <i>Endocrinology</i> , 2005, 146, 3900-3906.	2.8	88
79	Coexistence of salusin and vasopressin in the rat hypothalamo-hypophyseal system. <i>Neuroscience Letters</i> , 2005, 385, 110-113.	2.1	34
80	Laminar Shear Stress Up-Regulates Inducible Nitric Oxide Synthase in the Endothelium. <i>Hypertension Research</i> , 2004, 27, 93-99.	2.7	38
81	Antioxidant Effect of Adrenomedullin on Angiotensin II-Induced Reactive Oxygen Species Generation in Vascular Smooth Muscle Cells. <i>Endocrinology</i> , 2004, 145, 3331-3337.	2.8	75
82	Regulation of Adrenomedullin Gene Transcription and Degradation by the c-mycGene. <i>Endocrinology</i> , 2004, 145, 4244-4250.	2.8	18
83	Non-viral in vivo thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins. <i>European Journal of Cardio-thoracic Surgery</i> , 2004, 26, 995-1001.	1.4	10
84	Endothelin-1 Induces Cyclooxygenase-2 Expression and Generation of Reactive Oxygen Species in Endothelial Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S332-S335.	1.9	15
85	High Molecular Weight Form Insulin-like Growth Factor II-producing Mesenteric Sarcoma Causing Hypoglycemia. <i>Internal Medicine</i> , 2004, 43, 967-971.	0.7	8
86	Th2-predominant inflammation and blockade of IFN- $\hat{1}^3$ signaling induce aneurysms in allografted aortas. <i>Journal of Clinical Investigation</i> , 2004, 114, 300-308.	8.2	107
87	Th2-predominant inflammation and blockade of IFN- $\hat{1}^3$ signaling induce aneurysms in allografted aortas. <i>Journal of Clinical Investigation</i> , 2004, 114, 300-308.	8.2	166
88	Th2-predominant inflammation and blockade of IFN- $\hat{1}^3$ signaling induce aneurysms in allografted aortas. <i>Journal of Clinical Investigation</i> , 2004, 114, 739-739.	8.2	1
89	Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. <i>Nature Medicine</i> , 2003, 9, 1166-1172.	30.7	166
90	Adrenomedullin is an autocrine/paracrine growth factor for rat vascular smooth muscle cells. <i>Regulatory Peptides</i> , 2003, 112, 167-173.	1.9	36

#	ARTICLE	IF	CITATIONS
91	Coexpression of Calcitonin Receptor-Like Receptor and Receptor Activity-Modifying Protein 2 or 3 Mediates the Antimigratory Effect of Adrenomedullin. <i>Endocrinology</i> , 2003, 144, 447-453.	2.8	21
92	Urotensin II is an Autocrine/Paracrine Growth Factor for the Porcine Renal Epithelial Cell Line, LLCPK1. <i>Endocrinology</i> , 2003, 144, 1825-1831.	2.8	57
93	Octreotide-Sensitive Ectopic ACTH Production by Islet Cell Carcinoma with Multiple Liver Metastases. <i>Endocrine Journal</i> , 2003, 50, 135-143.	1.6	20
94	Regulation of Cell Growth and Apoptosis by Adrenomedullin. <i>Hypertension Research</i> , 2003, 26, S9-S14.	2.7	32
95	Cytokine-activated Jak-2 is involved in inducible nitric oxide synthase expression independent from NF- κ B activation in vascular smooth muscle cells. <i>Atherosclerosis</i> , 2002, 160, 123-132.	0.8	23
96	Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. <i>Cancer Research</i> , 2002, 62, 13-7.	0.9	418
97	Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. <i>American Journal of Kidney Diseases</i> , 2001, 37, 477-483.	1.9	70
98	Role of Endothelin-1/Endothelin Receptor System in Endotoxic Shock Rats.. <i>Hypertension Research</i> , 2001, 24, 119-126.	2.7	31
99	Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. <i>Journal of Hypertension</i> , 2001, 19, 2185-2190.	0.5	216
100	A Patient with Type 1 Diabetes Mellitus and Cerebellar Ataxia Associated with High Titer of Circulating Anti-Glutamic Acid Decarboxylase Antibodies.. <i>Endocrine Journal</i> , 2001, 48, 261-268.	1.6	17
101	Antiangiogenesis signals by endostatin. <i>FASEB Journal</i> , 2001, 15, 1044-1053.	0.5	190
102	Adrenomedullin Stimulates Proline-Rich Tyrosine Kinase 2 in Vascular Smooth Muscle Cells. <i>Endocrinology</i> , 2001, 142, 564-572.	2.8	42
103	Antiangiogenesis signals by endostatin. <i>FASEB Journal</i> , 2001, 15, 1044-1053.	0.5	43
104	Adrenomedullin Stimulates Proline-Rich Tyrosine Kinase 2 in Vascular Smooth Muscle Cells. <i>Endocrinology</i> , 2001, 142, 564-572.	2.8	15
105	Thymic Hyperplasia as a Source of Ectopic ACTH Production.. <i>Endocrine Journal</i> , 2000, 47, 487-492.	1.6	15
106	Suppression of Integrin α_v Expression by Endothelin-1 in Vascular Smooth Muscle Cells.. <i>Hypertension Research</i> , 2000, 23, 643-649.	2.7	12
107	Cytokine-Activated p42/p44 MAP Kinase Is Involved in Inducible Nitric Oxide Synthase Gene Expression Independent from NF- κ B Activation in Vascular Smooth Muscle Cells.. <i>Hypertension Research</i> , 2000, 23, 659-667.	2.7	17
108	Endothelin-1 Inhibits Apoptosis of Vascular Smooth Muscle Cells Induced by Nitric Oxide and Serum Deprivation via MAP Kinase Pathway. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 989-997.	2.4	90

#	ARTICLE	IF	CITATIONS
109	Differential Inhibitory Actions by Glucocorticoid and Aspirin on Cytokine-Induced Nitric Oxide Production in Vascular Smooth Muscle Cells*. Endocrinology, 1999, 140, 2183-2190.	2.8	46
110	Induction of Max by Adrenomedullin and Calcitonin Gene-Related Peptide Antagonizes Endothelial Apoptosis. Molecular Endocrinology, 1999, 13, 1353-1363.	3.7	87
111	Adrenomedullin Receptor Antagonism by Calcitonin Gene-Related Peptide(8-37) Inhibits Carotid Artery Neointimal Hyperplasia After Balloon Injury. Circulation Research, 1999, 85, 1199-1205.	4.5	24
112	Natriuretic Peptides and Nitric Oxide Induce Endothelial Apoptosis via a cGMP-Dependent Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 140-146.	2.4	102
113	Induction of Max by Adrenomedullin and Calcitonin Gene-Related Peptide Antagonizes Endothelial Apoptosis. Molecular Endocrinology, 1999, 13, 1353-1363.	3.7	32
114	Down-regulation of adenylate cyclase coupled to adrenomedullin receptor in vascular smooth muscle cells. European Journal of Pharmacology, 1998, 352, 131-134.	3.5	22
115	Transfection of Inducible Nitric Oxide Synthase Gene Causes Apoptosis in Vascular Smooth Muscle Cells. Circulation, 1998, 98, 1212-1218.	1.6	97
116	Adrenomedullin as a Novel Growth-Promoting Factor for Cultured Vascular Smooth Muscle Cells: Role of Tyrosine Kinase-Mediated Mitogen-Activated Protein Kinase Activation1. Endocrinology, 1998, 139, 3432-3441.	2.8	97
117	Endothelin-1 Is a Potent Survival Factor for c-Myc-Dependent Apoptosis. Molecular Endocrinology, 1998, 12, 172-180.	3.7	66
118	NO Inhibits Cytokine-Induced iNOS Expression and NF- κ B Activation by Interfering With Phosphorylation and Degradation of I κ B-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1796-1802.	2.4	166
119	Role of Nuclear Factor- κ B Activation in Cytokine- and Sphingomyelinase-Stimulated Inducible Nitric Oxide Synthase Gene Expression in Vascular Smooth Muscle Cells**This work was supported in part by grants-in-aid from the Ministry of Education, Science, and Culture and the Ministry of Health and Welfare of Japan.. Endocrinology, 1998, 139, 4506-4512.	2.8	47
120	Abnormal FSH Hypersecretion as an Endocrinological Manifestation of POEMS Syndrome.. Endocrine Journal, 1998, 45, 131-134.	1.6	8
121	Endothelin-B Receptor-Mediated Suppression of Endothelial Apoptosis. Journal of Cardiovascular Pharmacology, 1998, 31, S138-S141.	1.9	28
122	Endothelin-1 Is a Potent Survival Factor for c-Myc-Dependent Apoptosis. Molecular Endocrinology, 1998, 12, 172-180.	3.7	16
123	Adrenomedullin as an Autocrine/Paracrine Apoptosis Survival Factor for Rat Endothelial Cells*. Endocrinology, 1997, 138, 2615-2620.	2.8	213
124	Biphasic Regulation of the Preproendothelin-1 Gene by c-myc*. Endocrinology, 1997, 138, 4584-4590.	2.8	13
125	Endothelin-1 as an Autocrine/Paracrine Apoptosis Survival Factor for Endothelial Cells. Hypertension, 1997, 30, 1198-1203.	2.7	148
126	Adrenomedullin as an Autocrine/Paracrine Apoptosis Survival Factor for Rat Endothelial Cells. Endocrinology, 1997, 138, 2615-2620.	2.8	73

#	ARTICLE	IF	CITATIONS
127	Attenuation of atrial natriuretic peptide response to sodium loading after cardiac operation. Journal of Thoracic and Cardiovascular Surgery, 1995, 110, 75-80.	0.8	11
128	Pathophysiological Role of Magnesium in Familial Bartter's Syndrome.. Internal Medicine, 1994, 33, 1-5.	0.7	3
129	Atrial Natriuretic Peptide Response to Unilateral Pulmonary Artery Occlusion. Chest, 1994, 106, 1381-1386.	0.8	2
130	Effects of dietary protein restriction on hemodynamics in chronic renal failure. Kidney International, 1993, 43, 443-447.	5.2	7
131	Atrial Natriuretic Peptide in the Pericardial Fluid of Patients with Heart Disease. Clinical Science, 1993, 85, 165-168.	4.3	26
132	Increased production of endothelin-1 in patients with inflammatory arthritides. Arthritis and Rheumatism, 1992, 35, 397-400.	6.7	63
133	Effect of Low-Protein, Very-Low-Phosphorus Diet on Diabetic Renal Insufficiency With Proteinuria. American Journal of Kidney Diseases, 1991, 18, 26-32.	1.9	23
134	Endothelin and raynaud's phenomenon. American Journal of Medicine, 1991, 90, 130-132.	1.5	30
135	Endothelin-3 stimulates production of endothelium-derived nitric oxide via phosphoinositide breakdown. Biochemical and Biophysical Research Communications, 1991, 174, 228-235.	2.1	44
136	Plasma Endothelin-1 Levels in Patients with Diabetes Mellitus With or Without Vascular Complication. Journal of Cardiovascular Pharmacology, 1991, 17, S475-476.	1.9	35
137	Endothelin-1 as an Autocrine/Paracrine Factor for Human Tumor Cell Lines. Journal of Cardiovascular Pharmacology, 1991, 17, S76-78.	1.9	7
138	Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney International, 1991, 39, 307-311.	5.2	138
139	Decreased Fractional Excretion of Urate as an Indicator of Prerenal Azotemia. American Journal of Nephrology, 1990, 10, 489-494.	3.1	22
140	Diabetic Hypouricemia as an Indicator of Clinical Nephropathy. American Journal of Nephrology, 1990, 10, 115-122.	3.1	31
141	Postural Change and Volume Expansion Affect Plasma Endothelin Levels. JAMA - Journal of the American Medical Association, 1990, 263, 661.	7.4	34
142	Low-protein diet and progression of renal disease in diabetic nephropathy. Lancet, The, 1990, 335, 411-412.	13.7	7
143	Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line. Biochemical and Biophysical Research Communications, 1990, 169, 578-584.	2.1	123
144	Degradation of atrial natriuretic peptide in dogs. European Journal of Endocrinology, 1989, 120, 170-174.	3.7	11

#	ARTICLE	IF	CITATIONS
145	Effect of endothelin-1 on release of arginine-vasopressin from perfused rat hypothalamus. Biochemical and Biophysical Research Communications, 1989, 163, 1332-1337.	2.1	103
146	Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochemical and Biophysical Research Communications, 1989, 160, 93-100.	2.1	325
147	Concomitant secretion of big endothelin and its C-terminal fragment from human and bovine endothelial cells. Biochemical and Biophysical Research Communications, 1989, 162, 217-223.	2.1	53
148	Vasoconstrictor-induced heterologous down-regulation of vascular atrial natriuretic peptide receptor. European Journal of Pharmacology, 1989, 164, 603-606.	3.5	23
149	Specific receptor for endothelin in cultured rat cardiocytes. Biochemical and Biophysical Research Communications, 1989, 160, 1438-1444.	2.1	82
150	Secondary polycythemia associated with multiple myeloma.. Japanese Journal of Medicine, 1989, 28, 396-398.	0.1	8
151	Brain natriuretic peptide interacts with atrial natriuretic peptide receptor in cultured rat vascular smooth muscle cells. FEBS Letters, 1988, 238, 415-418.	2.8	34
152	DIFFERENTIATING GLOMERULAR AND NON-GLOMERULAR HAEMATURIA. Lancet, The, 1988, 332, 446-447.	13.7	2
153	RED-CELL-VOLUME DISTRIBUTION CURVES IN DIAGNOSIS OF GLOMERULAR AND NON-GLOMERULAR HAEMATURIA. Lancet, The, 1988, 331, 908-911.	13.7	48
154	Diabetic Renal Hypouricemia. Archives of Internal Medicine, 1987, 147, 225.	3.8	33
155	Diffuse Intrapulmonary Hemorrhage and Renal Failure in Adult Henoch-Schönlein Purpura. American Journal of Nephrology, 1987, 7, 140-142.	3.1	22
156	Hypouricemia due to Increased Tubular Urate Secretion. Nephron, 1987, 45, 31-34.	1.8	14
157	USE OF AUTOANALYSER TO EXAMINE URINARY-RED-CELL MORPHOLOGY IN THE DIAGNOSIS OF GLOMERULAR HAEMATURIA. Lancet, The, 1986, 328, 781-782.	13.7	43
158	Hypouricemia in the Syndrome of Inappropriate Secretion of Antidiuretic Hormone. Nephron, 1986, 42, 183-184.	1.8	3
159	Renal Handling of Urate in the Syndrome of Inappropriate Secretion of Antidiuretic Hormone. Archives of Internal Medicine, 1985, 145, 2045.	3.8	13
160	Hypouricemia and Renal Tubular Urate Secretion-Reply. Archives of Internal Medicine, 1983, 143, 1634.	3.8	0
161	Increased Urinary Kallikrein-Like Activity in the Syndrome of Inappropriate Secretion of Antidiuretic Hormone. Nephron, 1983, 35, 39-48.	1.8	8
162	Hypouricemia due to an Increment in Renal Tubular Urate Secretion. Archives of Internal Medicine, 1982, 142, 1855.	3.8	23

#	ARTICLE	IF	CITATIONS
163	Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide. Nephrology, 0, , .	1.6	0
164	ANGT_HUMAN[448â€“462], an Anorexigenic Peptide Identified using Plasma Peptidomics. Journal of the Endocrine Society, 0, , .	0.2	1